TY - JOUR
T1 - Laboratory and clinical studies on cefprozil granules in pediatrics
AU - Akita, Hlronobu
AU - Sato, Yoshitake
AU - Iwata, Satoshi
AU - Sunakawa, Keisuke
N1 - Copyright:
Copyright 2016 Elsevier B.V., All rights reserved.
PY - 1992/1
Y1 - 1992/1
N2 - Fundamental and clinical effects of cefprozil (CFPZ, BMY-28100) granules, a new oral cephalosporin antibiotic, in pediatric field were investigated. The result obtained were summarized as follows. 1. CFPZ (10% granules) was given to 1 child in a single dose of 7.5 mgAg. The peak serum concentration of CFPZ was 4.51 μg/ml at 2 hours after administration. Half-life and AUC values were 0.98 hour and 20.7 μg.hr/ml. The mean peak urinary concentrations of CFPZ and 6 hours recovery rates were over 200 μg/ml at 2-6 hours and 27.6%, respectively. 2. Clinical efficacy of CFPZ was investigated in a total of 41 children, including 14 with upper respiratory tract infections, 6 with acute bronchitis and pneumonia, 2 with acute otitis media, 3 with skin and soft tissue infections and 16 with urinary tract infections. The clinical efficacy rate was 95.1%. The bacteriological eradication rate was 84.6%. 3. Two patients showed abnormal laboratory test results. One had elevations of both GOT and GPT, and another had eosinophilia which were attributed to this antibiotic as side effects.
AB - Fundamental and clinical effects of cefprozil (CFPZ, BMY-28100) granules, a new oral cephalosporin antibiotic, in pediatric field were investigated. The result obtained were summarized as follows. 1. CFPZ (10% granules) was given to 1 child in a single dose of 7.5 mgAg. The peak serum concentration of CFPZ was 4.51 μg/ml at 2 hours after administration. Half-life and AUC values were 0.98 hour and 20.7 μg.hr/ml. The mean peak urinary concentrations of CFPZ and 6 hours recovery rates were over 200 μg/ml at 2-6 hours and 27.6%, respectively. 2. Clinical efficacy of CFPZ was investigated in a total of 41 children, including 14 with upper respiratory tract infections, 6 with acute bronchitis and pneumonia, 2 with acute otitis media, 3 with skin and soft tissue infections and 16 with urinary tract infections. The clinical efficacy rate was 95.1%. The bacteriological eradication rate was 84.6%. 3. Two patients showed abnormal laboratory test results. One had elevations of both GOT and GPT, and another had eosinophilia which were attributed to this antibiotic as side effects.
UR - http://www.scopus.com/inward/record.url?scp=0027080162&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027080162&partnerID=8YFLogxK
U2 - 10.11553/antibiotics1968b.45.1526
DO - 10.11553/antibiotics1968b.45.1526
M3 - Article
C2 - 1494235
AN - SCOPUS:0027080162
SN - 0368-2781
VL - 45
SP - 1526
EP - 1536
JO - The Journal of antibiotics. Ser. B
JF - The Journal of antibiotics. Ser. B
IS - 11
ER -